Impact of rheumatoid arthritis treatments on cancer outcomes
Effects of biologic and targeted therapies for rheumatoid arthritis on cancer outcomes
This study is looking at how certain treatments for rheumatoid arthritis might impact cancer outcomes for people who have both conditions, so we can better understand how to help those facing the challenges of managing both RA and cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10654754 on NIH RePORTER |
What this research studies
This research investigates how biologic and targeted therapies used to treat rheumatoid arthritis (RA) affect cancer outcomes in patients who have both RA and cancer. By analyzing data from various cancer registries and health records, the study aims to understand the relationship between these therapies and cancer progression or survival rates. The goal is to provide insights that can help guide treatment decisions for patients facing the dual challenges of RA and cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with both rheumatoid arthritis and cancer.
Not a fit: Patients with rheumatoid arthritis who do not have a concurrent cancer diagnosis may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with rheumatoid arthritis who also have cancer, enhancing their survival and quality of life.
How similar studies have performed: Previous research has shown promising results in understanding the effects of immunomodulatory therapies on cancer outcomes, but this specific investigation is addressing a relatively novel area.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Suarez-Almazor, Maria E — University of Tx Md Anderson Can Ctr
- Study coordinator: Suarez-Almazor, Maria E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.